Jason Kolbert

H.C. Wainwright & Co.

Image: Jason Kolbert

Jason Kolbert is managing director, research with the H.C. Wainwright & Co. He formerly was a senior analyst and head of healthcare at Maxim Group. Kolbert's career began as a chemist in the pharmaceutical industry, and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, he joined Salomon Smith Barney as a research associate, which evolved into an 18-year career on Wall Street as a ranked biotechnology analyst. His focus is across several therapeutic areas, with an emphasis in antiviral medicine, regenerative medicine, oncology and immunology (cell therapy). Kolbert is noted for being among the first analysts to focus on the changing landscape for Hepatitis C therapy. Kolbert spent seven years at Citi Group as a traditional sellside analyst, followed by seven years on the buy side as a portfolio manager with the Susquehanna International Group. Kolbert recently returned to his analyst role after spending a year as the head of business development for a public cell therapy company.

Recent Quotes

"SNGX announced today that the company has received an additional $2M in funding."

— Jason Kolbert, Maxim Group (6/21/17)
more >



Due to permission requirements, not all quotes are shown.